|Type||Buy / Hold / Sell|
|Year End 31st Dec||Unit||2018||2019||2020||2021||2022||2023E||2024E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.
- Bryan Hanson CHM (54)
- Suketu Upadhyay CFO (51)
- Wilfred Van Zuilen CEX
- Sang Yi CEX (58)
- Ivan Tornos COO (45)
- Chad Phipps SVP (49)
- Keri Mattox SVP
- Rachel Ellingson SVP (51)
- Ellison Humphrey SVP
- Nitin Goyal CTO
- Derek Davis CAO (52)
- Christopher Begley LED (68)
- Betsy Bernard IND (65)
- Michael Farrell IND (49)
- Robert Hagemann IND (64)
- Arthur Higgins IND (65)
- Maria Hilado IND (57)
- Syed Jafry IND (57)
- Sreelakshmi Kolli IND (46)
- Michael Michelson IND (69)
Upcoming Events for ZBH
Q4 2023 Zimmer Biomet Holdings Inc Earnings Release
Q1 2024 Zimmer Biomet Holdings Inc Earnings Release
Zimmer Biomet Holdings Inc Annual Shareholders Meeting
As of Today at 18:24 UTC, shares in Zimmer Biomet Holdings are trading at $113.43. This share price information is delayed by 15 minutes.
Shares in Zimmer Biomet Holdings last closed at $113.43 and the price had moved by -3.88% over the past 365 days. In terms of relative price strength the Zimmer Biomet Holdings share price has underperformed the S&P500 Index by -15.12% over the past year.
The overall consensus recommendation for Zimmer Biomet Holdings is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Zimmer Biomet Holdings dividend yield is 0.85% based on the trailing twelve month period.
Last year, Zimmer Biomet Holdings paid a total dividend of $0.96, and it currently has a trailing dividend yield of 0.85%. We do not have any data on when Zimmer Biomet Holdings is to next pay dividends.
We do not have data on when Zimmer Biomet Holdings is to next pay dividends. The historic dividend yield on Zimmer Biomet Holdings shares is currently 0.85%.
To buy shares in Zimmer Biomet Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $113.43, shares in Zimmer Biomet Holdings had a market capitalisation of $23.70bn.
Here are the trading details for Zimmer Biomet Holdings:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ZBH
Based on an overall assessment of its quality, value and momentum Zimmer Biomet Holdings is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Zimmer Biomet Holdings is $128.75. That is 13.51% above the last closing price of $113.43.
Analysts covering Zimmer Biomet Holdings currently have a consensus Earnings Per Share (EPS) forecast of $7.51 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zimmer Biomet Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -18.04%.
As of the last closing price of $113.43, shares in Zimmer Biomet Holdings were trading -9.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zimmer Biomet Holdings PE ratio based on its reported earnings over the past 12 months is 14.36. The shares last closed at $113.43.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Zimmer Biomet Holdings' management team is headed by:
- Bryan Hanson - CHM
- Suketu Upadhyay - CFO
- Wilfred Van Zuilen - CEX
- Sang Yi - CEX
- Ivan Tornos - COO
- Chad Phipps - SVP
- Keri Mattox - SVP
- Rachel Ellingson - SVP
- Ellison Humphrey - SVP
- Nitin Goyal - CTO
- Derek Davis - CAO
- Christopher Begley - LED
- Betsy Bernard - IND
- Michael Farrell - IND
- Robert Hagemann - IND
- Arthur Higgins - IND
- Maria Hilado - IND
- Syed Jafry - IND
- Sreelakshmi Kolli - IND
- Michael Michelson - IND